In a report released today, Peter Lawson from Barclays maintained a Hold rating on Blueprint Medicines (BPMC – Research Report), with a price ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Chemomab Therapeutics (CMMB – Research Report) ...

BPMC stock opened at $93.94 on Thursday. Blueprint Medicines has a 1-year low of $77.57 and a 1-year high of $121.90. The business has a 50-day moving average price of $99.61 and a 200 day moving ...

SM Market Opportunity: Projected peak value of $4 billion, with AYVAKIT as the anchor. Blueprint Medicines Corp (NASDAQ:BPMC) reported a significant annual growth of 135% in product revenue for ...

At this time, I would like to welcome everyone to the Blueprint Medicines 4Q and FY 2024 earnings release and conference call. Thank you, Nadia. Good morning, everyone, and welcome to Blueprint ...

My name is Nadia, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines 4Q and FY 2024 earnings release and conference call. Thank you, ...

Revenue: US$508.8m (up 104% from FY 2023). Net loss: US$67.1m (loss narrowed by 87% from FY 2023). US$1.07 loss per share (improved from US$8.37 loss in FY 2023). Revenue was in line with analyst ...

Roche has signed a global collaboration worth up to $1.7 billion with cancer drugs firm Blueprint Medicines based around pralsetinib, a drug that targets tumours with RET mutations.